GlassScriptPhysician profile
Thomas J Vinton
NPI 1184688939
$2,571.06
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,160 · 2020: $399 · 2022: $12.42.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $308.94 | 2019-2020 | |
| Amgen INC. | $305.14 | 2019-2020 | |
| Novo Nordisk INC | $300.45 | 2019 | |
| Glaxosmithkline, LLC. | $275.08 | 2019-2020 | |
| Allergan, INC. | $237.54 | 2019-2020 | |
| Lilly USA, LLC | $163.43 | 2019 | |
| Astellas Pharma US INC | $135.98 | 2019 | |
| Amarin Pharma, INC. | $122.28 | 2019 | |
| Antares Pharma, INC. | $110.71 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $95.84 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.74 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $65.23 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $47.70 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $45.91 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.22 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $37.75 | 2019 | |
| Mylan Specialty L.P. | $36.57 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $30.09 | 2019 | |
| Upsher-Smith Laboratories LLC | $20.37 | 2019 | |
| Boston Scientific Corporation | $15.94 | 2019 | |
| Genentech USA, INC. | $14.21 | 2019 | |
| Pfizer INC. | $13.43 | 2020 | |
| Eisai INC. | $12.71 | 2019 | |
| Abbvie INC. | $12.42 | 2022 | |
| Promius Pharma LLC | $12.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.32 | 2019 | |
| Radius Health, INC. | $11.29 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.25 | 2019 | |
| Shire North American Group INC | $11.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Vinton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.